Zoetis Inc. with ticker code (ZTS) have now 14 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $260.00 and $195.00 with the average share target price sitting at $224.42. (at the time of writing). Now with the previous closing price of $165.52 this would indicate that there is a potential upside of 35.6%. Also worth taking note is the 50 day moving average now sits at $183.58 and the 200 moving average now moves to $181.03. The company has a market cap of 77.24B. The stock price for the company is currently $168.70 USD
The potential market cap would be $104,728,650,709 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 33.27, revenue per share of $18.53 and a 13.15% return on assets.
Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. It commercializes products across eight core species: dogs, cats and horses and cattle, swine, poultry, fish and sheep and within product categories, such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company operates through two segments: the United States and International. Within each of these operating segments, it offers a product portfolio for both companion animal and livestock customers. The Company market its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company’s products are sold in more than 100 countries.
